Litigation Details for Pozen Inc. v. Teva Pharmaceuticals USA Inc. (E.D. Tex. 2009)

Pozen Inc. v. Teva Pharmaceuticals USA Inc. (E.D. Tex. 2009)

Docket	6:09-cv-00182	Date Filed	2009-04-24
Court	District Court, E.D. Texas	Date Terminated	2011-08-05
Cause	35:271 Patent Infringement	Assigned To	Leonard E. Davis
Jury Demand	None	Referred To
Patents	7,332,183
Link to Docket	External link to docket

Details for Pozen Inc. v. Teva Pharmaceuticals USA Inc. (E.D. Tex. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-04-24				External link to document

Pozen Inc. v. Teva Pharmaceuticals USA Inc. Litigation Summary and Patent Analysis, 6:09-cv-00182

Last updated: August 3, 2026

Pozen Inc. v. Teva Pharmaceuticals USA Inc., No. 6:09-cv-00182, was an ANDA patent case involving Treximet, a fixed-dose combination of sumatriptan and naproxen for acute migraine treatment. Pozen alleged that Teva’s abbreviated new drug application infringed patents covering the combination product and its therapeutic use. The case did not produce a reported final merits judgment establishing invalidity or infringement. The dispute was resolved through settlement and dismissal rather than a publicly reported trial decision.

What drug and patents were at issue in Pozen v. Teva?

The case concerned Treximet, which combines:

Product	Active ingredients	Original innovator	FDA product
Treximet	Sumatriptan succinate and naproxen sodium	Pozen Inc.; later commercialized by GlaxoSmithKline	NDA 021-862

Treximet was designed to combine a serotonin 5-HT1B/1D agonist, sumatriptan, with the nonsteroidal anti-inflammatory drug naproxen. The product used a formulation intended to deliver the two active ingredients in a coordinated manner.

Pozen asserted at least the following patents in the Treximet patent litigation:

Patent	General subject matter	Relevance to Treximet
U.S. Patent No. 6,060,499	Pharmaceutical compositions containing a triptan and an NSAID	Core combination-product protection
U.S. Patent No. 6,586,458	Methods and pharmaceutical compositions for treating migraine	Method-of-use and product-related protection

The patents were also litigated in related Treximet cases against other generic applicants. The Federal Circuit later analyzed the same patent family and technology in Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012).

What did Pozen allege against Teva?

Pozen filed the action after receiving a Paragraph IV certification from Teva under the Hatch-Waxman Act. Teva’s ANDA sought FDA approval to market a generic version of Treximet before expiration of the asserted patents.

The complaint alleged that Teva’s proposed generic product would infringe claims directed to:

• A pharmaceutical composition containing sumatriptan and naproxen.
• Specified amounts or relationships between the active ingredients.
• Treatment of migraine using the combination.
• Formulation characteristics associated with delivery of the two drugs.

The statutory framework treated the Paragraph IV certification as an artificial act of infringement under 35 U.S.C. § 271(e)(2). Pozen’s filing triggered the statutory 30-month stay of FDA approval for Teva’s ANDA, subject to earlier termination or modification under the Hatch-Waxman framework.

What was the procedural history of case 6:09-cv-00182?

The material procedural history is summarized below.

Event	Significance
2009	Pozen filed suit against Teva after Teva submitted an ANDA with a Paragraph IV certification
2009-2011	The parties litigated patent scope, infringement, and validity issues
2011	The court issued interlocutory rulings in the patent dispute, including claim-construction and dispositive-motion proceedings
Settlement period	Pozen and Teva resolved the action without a reported final trial judgment
Final disposition	The case was dismissed pursuant to settlement

The docket number identifies the matter as No. 6:09-cv-00182. Publicly reported decisions do not establish a final judgment holding that Teva infringed, or that the asserted patents were invalid. That distinction matters for evaluating the precedential value of the case. The action was a private Hatch-Waxman dispute, not a Federal Circuit merits decision.

Was there a Paragraph IV challenge to Treximet?

Yes. Teva’s ANDA filing included a Paragraph IV certification challenging the enforceability, validity, or infringement position of the Treximet patents. Pozen’s lawsuit was based on that certification.

A Paragraph IV case does not mean that the generic applicant has admitted infringement. It means the applicant has certified that one or more Orange Book-listed patents are invalid, unenforceable, or will not be infringed by the proposed ANDA product.

The litigation therefore placed the following issues before the court:

1. Whether Teva’s proposed product fell within the asserted patent claims.
2. Whether the asserted claims were valid over the prior art.
3. Whether the patents were enforceable.
4. When Teva could obtain FDA approval and enter the market if the dispute settled.

What patent claims protected the Treximet formulation?

The principal technical issue was the combination of sumatriptan and naproxen in a single migraine product.

Combination-product claims

The ’499 patent was directed broadly to pharmaceutical compositions combining a triptan with an NSAID. The patent estate sought to prevent generic substitution through claims covering the active ingredients and their use in treating migraine.

The combination was commercially significant because sumatriptan and naproxen had different pharmacological mechanisms. The patent strategy did not depend only on claiming the individual molecules. It focused on their use together in a coordinated pharmaceutical product.

Method-of-use claims

The ’458 patent included method-oriented subject matter involving administration of the combination for migraine treatment. Method claims can create an additional barrier to ANDA approval, but their practical value depends on:

• The scope of the FDA-approved labeling.
• Whether the generic applicant can use a section viii statement or carve out the patented indication.
• Whether the proposed label still induces infringement.
• Whether the claim requires a specific dosing sequence or clinical result.

The Federal Circuit’s later decision in the related Par litigation shows that the Treximet patents were subject to substantial validity analysis, including obviousness arguments directed to the combination of known migraine therapies (Pozen Inc. v. Par Pharmaceutical, Inc., 2012).

What was the Orange Book status of Treximet patents?

The FDA Orange Book listed patents associated with NDA 021-862. The Treximet estate included the ’499 and ’458 patents, together with later-listed patents and related patent rights. Orange Book listing created the statutory framework for ANDA certifications and the 30-month stay.

Regulatory item	Treximet status
NDA	021-862
Dosage form	Oral tablet
Reference product	Treximet
ANDA pathway	Section 505(j)
Challenge mechanism	Paragraph IV certification
FDA approval effect	Patent certification and litigation affected approval timing

The Orange Book should be evaluated by edition because listings, delistings, pediatric extensions, and later patents can change over time. A patent appearing in the Orange Book does not establish that it is valid or infringed. It establishes that the patent is listed by the NDA holder for regulatory certification purposes.

When did the Treximet patents lose exclusivity?

The principal Treximet patents had different statutory expiration dates, and the effective generic-entry date depended on settlement terms, pediatric exclusivity, later patents, and regulatory approval.

Patent	Approximate term position	Business significance
’499 patent	Expired in the late 2010s	Core composition protection ended before the full later Treximet estate
’458 patent	Extended protection into the later 2010s or approximately 2020, depending on applicable term adjustments	Maintained a later barrier for certain product or use claims
Later Treximet patents	Potentially extended protection beyond the foundational patents	Could affect formulation, use, or commercial launch timing

Patent expiration alone did not determine Teva’s launch date. A generic applicant could face:

• A settlement-restricted launch date.
• Pediatric exclusivity.
• Later Orange Book-listed patents.
• Separate litigation involving a reformulated or modified product.
• FDA review delays or deficiencies.

For investment or launch analysis, the legally relevant date is the earliest date on which the ANDA could be approved and marketed under the settlement and all remaining regulatory restraints.

Did Pozen win the case against Teva?

No reported final merits ruling establishes that Pozen prevailed against Teva on infringement or validity.

The action ended through settlement and dismissal. As a result:

• There was no publicly reported final judgment of infringement.
• There was no publicly reported final judgment invalidating the asserted patents.
• The settlement terms did not provide a judicial determination of patent strength.
• The case had limited precedential value compared with the Federal Circuit’s later decision in the related Par litigation.

Settlement should not be treated as proof that Teva’s challenge lacked merit. Hatch-Waxman settlements commonly reflect a negotiated allocation of launch risk, litigation cost, regulatory timing, and commercial value.

What was the settlement and when could Teva launch?

The parties resolved the litigation under confidential or non-public settlement terms. Publicly available case materials do not establish a complete, definitive set of commercial terms sufficient to calculate Teva’s exact contractual launch date.

The settlement presumably addressed:

• Dismissal of Pozen’s claims.
• Teva’s ability to obtain approval and commercialize a generic Treximet product.
• The relationship between the settlement date and patent expiration.
• Potential restrictions associated with later-listed patents or regulatory exclusivity.

The absence of a public merits judgment means that Teva’s market-entry position must be analyzed from the settlement, Orange Book records, FDA approval history, and later commercial events rather than from a trial verdict.

How strong was Pozen’s Treximet patent estate?

The estate was commercially meaningful but legally exposed.

Strengths

• It covered a commercially differentiated combination product rather than only an unmodified active ingredient.
• The patents addressed both composition and treatment.
• The combination of composition claims and method claims created multiple infringement theories.
• Related litigation produced appellate review, confirming that the patents raised substantial and litigable issues.

Risks

• Sumatriptan and naproxen were individually known drugs.
• Generic defendants could argue that combining known agents was obvious.
• Method-of-use claims faced label-carveout and induced-infringement issues.
• Patent-term limits created a finite exclusivity period.
• The estate depended on claim construction and the specific composition of the ANDA product.

The later Par decision is more informative on patent strength than the Teva docket because it included appellate analysis of validity and infringement issues involving the Treximet technology.

Which companies challenged Treximet patents?

Treximet-related patent disputes involved multiple generic applicants, including Teva and Par Pharmaceutical. Other ANDA applicants were also involved in related litigation or patent challenges as the product approached loss of exclusivity.

The competitive landscape included:

Company	Role
Pozen	Original patent holder and product developer
GlaxoSmithKline	Commercial partner for Treximet
Teva	ANDA applicant and defendant in No. 6:09-cv-00182
Par Pharmaceutical	Defendant in related Treximet litigation
Later generic applicants	Potential entrants after patent and regulatory barriers declined

The market risk was therefore distributed across several potential entrants rather than limited to Teva.

What regulatory and commercial risks affected generic entry?

The main generic-entry risks were legal and regulatory.

FDA risks

Teva’s ANDA required FDA approval of a product pharmaceutically equivalent to Treximet and compliance with applicable labeling, manufacturing, and quality requirements. FDA approval did not eliminate patent risk. Approval and launch depended on the interaction between:

• ANDA review.
• Paragraph IV litigation.
• The 30-month stay.
• Patent expiration.
• Settlement restrictions.
• Pediatric exclusivity.
• Orange Book changes.

Manufacturing and formulation risks

Treximet’s combination formulation created manufacturing and intellectual-property issues beyond active-ingredient sourcing. A generic applicant had to produce a product meeting applicable requirements for:

• Strength.
• Dosage form.
• Dissolution.
• Stability.
• Content uniformity.
• Bioequivalence.
• Manufacturing controls.

A noninfringing formulation might reduce patent exposure but create additional development and regulatory risk.

Commercial risks

Treximet’s commercial value depended on continued prescribing of a branded combination product despite the availability of separate sumatriptan and naproxen products. Generic entry could produce rapid price erosion because pharmacy substitution and payer controls generally favor lower-cost alternatives.

The principal revenue exposure was the erosion of Treximet sales after the first approved generic. The erosion rate would depend on the number of entrants, authorized-generic arrangements, payer substitution, and whether the brand retained differentiated prescribing or reimbursement.

What patent litigation affects Treximet beyond the Teva case?

The related Pozen v. Par litigation is the most important reported proceeding for interpreting the Treximet patent estate. In that case, the Federal Circuit addressed patent validity and infringement issues involving the same general combination-product technology. The decision provides legal analysis that may inform risk assessment but does not convert the Teva settlement into a merits victory.

The broader litigation record shows that Treximet faced:

• Paragraph IV challenges.
• Obviousness attacks.
• Claim-construction disputes.
• Infringement disputes based on generic formulation details.
• Method-of-use and labeling issues.
• Settlement-driven launch timing.

Key Takeaways

• Pozen v. Teva, No. 6:09-cv-00182, was a Hatch-Waxman case involving generic Treximet.
• The dispute centered on U.S. Patent Nos. 6,060,499 and 6,586,458 and related Treximet patent rights.
• Teva challenged the listed patents through a Paragraph IV certification.
• The case ended through settlement and dismissal, not a reported final merits judgment.
• The Teva docket does not establish that Pozen won infringement or validity claims.
• The related Pozen v. Par Federal Circuit litigation provides stronger evidence for evaluating the patent estate.
• Generic launch timing depended on settlement terms, Orange Book listings, patent expiration, FDA approval, and any remaining regulatory exclusivity.
• Composition, method-of-use, formulation, and manufacturing issues all affected entry risk.
• The principal commercial threat was price erosion after the first approved generic Treximet product.

FAQs

Was Teva’s generic Treximet approved by the FDA?

The Teva litigation involved an ANDA seeking approval for a generic version of Treximet. The litigation record alone does not establish the full final FDA approval history or the precise date of any commercial launch.

Did Pozen receive a 30-month stay against Teva?

Pozen’s Paragraph IV lawsuit triggered the Hatch-Waxman framework for a potential 30-month stay of FDA approval. The stay could be shortened or otherwise affected by statutory and settlement events.

Did the Treximet settlement permit an authorized generic?

The publicly available litigation record does not establish whether the settlement included an authorized-generic arrangement. That issue must be distinguished from the dismissal of the patent action itself.

Are Treximet patents relevant to generic sumatriptan or naproxen products?

Treximet patents primarily targeted the combination product and its use. They did not automatically block standalone sumatriptan or naproxen products that fell outside the asserted claims.

Does Pozen v. Par control the result in Pozen v. Teva?

No. The Federal Circuit’s decision in Pozen v. Par is relevant precedent on related Treximet patent issues, but it did not adjudicate Teva’s ANDA or replace the settlement disposition in No. 6:09-cv-00182.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Pozen Inc. v. Teva Pharmaceuticals USA Inc., No. 6:09-cv-00182, U.S. District Court for the Eastern District of Texas.

3. Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012).

4. U.S. Patent No. 6,060,499. (2000). Pharmaceutical compositions for treating migraine. U.S. Patent and Trademark Office.

5. U.S. Patent No. 6,586,458. (2003). Pharmaceutical compositions and methods for treating migraine. U.S. Patent and Trademark Office.

6. Hatch-Waxman Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).